Catalog No.: PC-49196Not For Human Use, Lab Use Only.
BC18630 free base (BC 18630) is a small molecule inhibitor of the E3 ubiquitin ligase subunit DCAF7, potently inhibits SARS-CoV-2 infection with IC50 of 39 nM in cell-based assays.
BC18630 free base (BC 18630) is a small molecule inhibitor of the E3 ubiquitin ligase subunit DCAF7, potently inhibits SARS-CoV-2 infection with IC50 of 39 nM in cell-based assays.
BC18630 decreases TFEB ubiquitination and significantly reduces the measured interaction between DCAF7 and TFEB in nucleus of cells.
BC18630 attenuates a wide range of viral infections including SARS-CoV-2 infection, prevents virally-triggered TFEB degradation and dose-dependently reduces OC43 coronavirus infection, reduces HCoV-OC43 NP expression with IC50 of 0.3 uM.
BC18630 (oral BID at 20mg/kg and 50 mg/kg for 5 days) dose-dependently reduced lung viral titer (PFU) in Syrian hamster model of SARS-CoV-2 infection, significantly reduced SARS-CoV-2 N-protein (NP) in lung, also reduced the observed level of lung injury, with the higher dose particularly reducing inflammatory infiltrates.
Physicochemical Properties
M.Wt
337.386
Formula
C21H15N5
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
N-1H-indol-5-yl-2-pyridin-4-ylquinazolin-4-amine
References
1. Yuan Liu, et al. Res Sq. 2021 Apr 23;rs.3.rs-419305.
